Pharma Industry News

REGiMMUNE and Kiji Therapeutics to Merge

The merger will create a specialty company, REGiMMUNE/Kiji TX, for regulatory T cells.

The merger will create a specialty company, REGiMMUNE/Kiji TX, for regulatory T cells.

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

Leave a Comment

[mwai_chat window="true" fullscreen="true"]